[
    [
        {
            "time": "2019-01-08",
            "original_text": "Novartis Stock Is Poised to Rise Another 15% From Here",
            "features": {
                "keywords": [
                    "Novartis",
                    "Stock",
                    "Poised",
                    "Rise",
                    "15%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-01-08",
            "original_text": "Health Care Sector Update for 01/08/2019: AXSM, AKRX, NVS, JNJ, PFE, MRK, ABT, AMGN",
            "features": {
                "keywords": [
                    "Health",
                    "Care",
                    "Sector",
                    "Update",
                    "AXSM",
                    "AKRX",
                    "NVS",
                    "JNJ",
                    "PFE",
                    "MRK",
                    "ABT",
                    "AMGN"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 9,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-01-08",
            "original_text": "The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase",
            "features": {
                "keywords": [
                    "Daily",
                    "Biotech",
                    "Pulse",
                    "Amgen",
                    "Slashes",
                    "Cholesterol",
                    "Drug",
                    "Device",
                    "Prices",
                    "60%",
                    "Takeda",
                    "Completes",
                    "Shire",
                    "Purchase"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-01-08",
            "original_text": "Novartis: FDA Grants Crizanlizumab Breakthrough Therapy Designation",
            "features": {
                "keywords": [
                    "Novartis",
                    "FDA",
                    "Grants",
                    "Crizanlizumab",
                    "Breakthrough",
                    "Therapy",
                    "Designation"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]